<div id="readability-page-1"><div>Overview<ul><li>Veterinary pharma firm's 2025 revenue rose 7.9% at constant rates and scope</li><li>Company's companion animal segment grew 10.9%, driving overall revenue growth</li><li>Company expects 2026 revenue growth of 5.5% to 7.5% at constant rates and scope</li></ul>Outlook<ul><li>Virbac expects 2026 revenue growth between 5.5% and 7.5% at constant rates</li><li>Company anticipates 2026 adjusted operating income ratio around 17%</li><li>Thyronorm acquisition to contribute ~1 pt to 2026 revenue growth</li></ul>Result Drivers<ul><li>COMPANION ANIMAL GROWTH - Co reported 10.9% growth in companion animal segment, driven by new product launches and strong market demand</li><li>FARM ANIMAL SEGMENT - Farm animal segment saw 6.1% growth, supported by high sales of vaccines and parasiticides</li><li>U.S. MARKET PERFORMANCE - U.S. market contributed significantly with a 14.7% growth at CERS, driven by new product launches and existing product strength</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>Q4 Revenue</td></tr><tr><td>Beat/Miss</td><td></td></tr><tr><td>Actual</td><td>EUR 362 mln</td></tr><tr><td>Consensus Estimate</td><td></td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 7 &#34;strong buy&#34; or &#34;buy&#34;, 2 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the pharmaceuticals peer group is &#34;buy&#34;</li><li>Wall Street's median 12-month price target for Virbac SA is €407.00, about 14% above its January 16 closing price of €357.00</li><li>The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

Virbac's 2025 revenue increased by 7.9% at constant rates, driven by a 10.9% growth in its companion animal segment. The company anticipates a revenue growth of 5.5% to 7.5% for 2026, with an adjusted operating income ratio around 17%. The U.S. market showed significant performance with a 14.7% growth. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of €407.00, reflecting a 14% upside from its recent trading price of €357.00.

Reuters

iShares Biotechnology ETF

ALPS Medical Breakthrough

VG Health

Virax Biolabs

Virpax Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

VBI VACCINES INC CDA

SPDR S&P Biotech

iShares US Medical Devices

iShares US Pharma

iShares Global Healthcare

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

Health Care Select Sector SPDR

SPDR S&P Health Equip

France's Virbac 2025 revenue up 7.9% at constant rates